1,2,3,3a,8,8a-Hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indoles, a process for their preparation and their use as medicaments

Abstract: There are described compounds of the formula where (a) X is O or S; (b) R is H, loweralkyl, where Y is O or S; R₂ is loweralkyl, cycloalkyl, bicycloalkyl, cycloalkenyl, aryl, arylloweralkyl, heteroaryl or heteroarylloweral­ kyl, R₃ is H or lower alkyl or the group -NR₂R₃ taken as a whole is 1-pyrrolidinyl, 1-piperidinyl, 4-morpholinyl, 4-thiomorpholinyl, 1-­ piperazinyl, 4-methyl-1-piperazinyl or 2-(2,6-dichlorophenyl­ imino)-1-imidazolidinyl) and R₄ is hydrogen, loweralkyl, aryl­ loweralkyl, diarylloweralkyl, aryl or heteroaryl, (c) m is 1 or 2; (d) each Z is independently H, loweralkyl, halogen, nitro, -NH₂, loweralkylcarbonylamino, arylcarbonylamino, loweralkoxy­ carbonylamino or loweralkylamino, and (e) R₁ is H, loweralkyl, arylloweralkyl, heteroarylloweralkyl, cy­ cloalkylmethyl or loweralkenylmethyl, with the proviso that when X is O, m is 1, Z is H and R₁ is methyl, R is not -CONHCH₃, -CONHC₆H₅, hydrogen, methyl or ethyl, and that when X is O, m is 1 and Z and R are both hydrogen, R is not hydrogen or methyl, and pharmaceutically acceptable acid addi­ tion salts thereof which are useful as memory-enhancing and analgesic agents.

Description: The present invention relates to compounds of the formula I where Z is H and R is where R₂ is phenyl-C₁-C₆-alkyl, wherein the phenyl may be substituted with 1, 2 or 3 substituent groups each of which being independently C₁-C₆-alkyl, halogen, nitro, C₁-C₆-alkoxy, hydroxy or trifluoromethyl, or where Z is halogen or C₁-C₆-alkyl, R is H or where R₄ is C₁-C₆-alkyl, or phenyl, or R is wherein R₃ is C₁-C₆-alkyl, C₃-C₆-cycloalkyl, phenyl or phenyl-C₁-C₆-alkyl, wherein the phenyl may be substituted as indicated above, which are useful as memory-enhancing and analgesic agents, and to pharmaceutical compositions comprising an effective amount of such compounds. DE-A-2 839 279 discloses physostigmine derivatives having in 5-position a hydroxy-, alkoxy- or alkenoxy-group. The compounds are reported to show analgesic activity. EP-A1-0 154 864 discloses physostigmine derivatives having in 5-position the group RHN-COO-, wherein R is C₂-C₂₀-alkyl, cycloalkyl or aryl, which compounds are reported to show acetyl-cholinesterase inhibiting properties. The compounds of this invention are prepared by utilizing one or more of the steps described below. Throughout the description of the synthetic steps, the notations, Z, R, R₂, R₃, R₄ shall have the respective meanings given above unless otherwise stated or indicated. The heavy lines ( ) coming out of the 3a-carbon and 8a-carbon in formula I and other formulas presented in the specification and the appended claims signify that the substituents are above the average plane of the three-ring system. Thus, in formula (I) and other formulas, the substituents at the 3a- and 8a- carbons are cis inasmuch as they are on the same side of the three ring system. Where said substituents are both below the average plane of the three ring system, they are also cis. The first type of cis configuration will be referred to as 3aS-cis where both substituents are above the average plane of the ring and the second type will be referred to as 3aR-cis where both substituents are below the average plane of the ring. These two types of configuration are depicted below. It is the intent of the present inventors to claim both of said cis compounds, namely, 3aS-cis compound and 3aR-cis compound for each structural formula, although only the former type is shown in the specification and the appended claims in order to save space. It is also the intent of the present inventors to claim all mixtures of the 3aS-cis and 3aR-cis compounds including the racemic mixture (1:1 ratio of 3aS-cis:3aR-cis). STEP A Starting with a compound of formula IV (where Z is hydrogen, C₁-C₆-alkyl or halogen) and utilizing the synthetic scheme disclosed in Julian et al., J. Am. Chem. Soc. 1935 , 563-566 and 755-757, one can prepare compounds of the formulas VIII through XI. The synthetic scheme is outlined below, but for details the reader is referred to the original articles. For details of the optical resolution steps involved in the synthetic scheme, the reader is referred to Schönenberger et al., J. Med. Chem., 1986 , Volume 29, 2268-2273; and Schönenberger et al., Helv. Chim. Acta, 1986 , Volume 69, 283-287 and 1486-1497. (Z = H, C₁-C₆-alkyl or halogen) STEP B As an alternative to STEP A above, one can introduce Cl or Br into the C₇-position of compound Xa and obtain compound Xb depicted below (where Z is Cl or Br) by reacting compound Xa with N-chlorosuccinimide or N-bromosuccinimide, respectively, according to a routine procedure known in the art. (Z = Cl or Br) STEP C Compound XI is reacted with an isocyanate of the formula R₂-N=C=O to afford a compound of formula XII below. Typically, compound XI and the isocyanate are dissolved in a suitable solvent such as anhydrous tetrahydrofuran which has previously been degassed. Degassing is helpful because compound XI is susceptible to air oxidation. It is also helpful to add a catalytic amount (less than equivalent amount) of sodium metal to the resultant solution in order to facilitate the reaction. Said reaction is usually conducted between room temperature and about 7⊘°C. Reflux condition is particularly convenient. STEP D A compound of formula XIII can be prepared by reacting a carboxylic acid of the formula R₄-COOH with 1,1'-carbonyldiimidazole and thereafter adding to the mixture a compound of formula (XI) obtained from one of the foregoing steps. The compounds of formula I of the present invention are useful in the treatment of various memory dysfunctions characterized by decreased cholinergic function, such as Alzheimer's disease. This utility is manifested by the ability of these compounds to inhibit the enzyme acetylcholinesterase and thereby increase acetylcholine levels in the brain. Cholinesterase Inhibition Assay Cholinesterases are found throughout the body, both in brain and in serum. However, only brain acetylcholinesterase (AChE) distribution is correlated with central cholinergic innervation. This same innervation is suggested to be weakened in Alzheimer patients. Therefore, specific inhibitors of brain AChE (as opposed to serum AChE) will give rise to fewer side effects and thus lower toxicity than physostigmine (an unspecific AChE inhibitor). We have determined in vitro inhibition of acetylcholinesterase activity in rat striatum and in vitro inhibition of butyrylcholinesterase activity in human serum according to the methods described below. Results of some of the compounds of this invention as well as those of physostigmine are presented in Table 1. In Vitro Inhibition of Acetylcholinesterase Activity in Rat Striatum Acetylcholinesterase (AChE), which is sometimes called true or specific cholinesterase, is found in nerve cells, skeletal muscle, smooth muscle, various glands and red blood cells. AChE may be distinguished from other cholinesterases by substrate and inhibitor specificities and by regional distribution. Its distribution in brain correlates with cholinergic innervation and subfractionation shows the highest level in nerve terminals. It is generally accepted that the physiological role of AChE is the rapid hydrolysis and inactivation of acetylcholine. Inhibitors of AChE show marked cholinomimetic effects in cholinergically-innervated effector organs and have been used therapeutically in the treatment of glaucoma, myasthenia gravis and paralytic ileus. However, recent studies have suggested that AChE inhibitors may also be beneficial in the treatment of Alzheimer's dementia. The method described below was used in this invention for assaying cholinesterase activity. This is a modification of the method of Ellman et al., Biochem. Pharmacol. 7 , 88 (1961). Procedure A. Reagents 1. ⊘.⊘5 M Phosphate buffer, pH 7.2 a) 6.85 g NaH₂PO₄ . H₂O/1⊘⊘ ml distilled H₂O b) 13.4⊘ g Na₂HPO₄ . 7H₂O/1⊘⊘ ml distilled H₂O c) add a) to b) until pH reaches 7.2 d) Dilute 1:1⊘ 2. Chromogen-substrate buffer a) 9.9 mg 5,5-dithiobisnitrobenzoic acid (DTNB) (⊘.25 mM) b) 99 mg s-acetylthiocholine chloride (5 mM) c) q.s. to 1⊘⊘ ml with ⊘.⊘5 M phosphate buffer, pH 7.2 (reagent 1) 3. For most assays, a 2 mM stock solution of the test drug is made up in a suitable solvent and serially diluted such that the final concentration in the preincubation step ranges from 10⁻³ to 10⁻⁶ M. Different concentrations may be used depending on the potency of the drug. B. Tissue Preparation Male Wistar rats are decapitated, brains rapidly removed, corpora striata dissected free, weighed and homogenized in 19 volumes (approximately 7 mg protein/ml) of ⊘.⊘5 M phosphate buffer, pH 7.2 using a Potter-Elvehjem homogenizer. A 5⊘ microliter aliquot of the homogenate is added to 5⊘ microliter vehicle of various concentrations of the test drug and preincubated for 1⊘ minutes at room temperature. C. Assay 1. For routine IC₅ ⊘ determinations the Abbott Bichromatic Analyzer, ABA-1⊘⊘, is used to determine acetylcholinesterase activity. Instrument settings Filter 45⊘-415 Incubation temperature 3⊘°C Decimal point ⊘⊘⊘⊘. Analysis time 5 minutes Carousel Revolution 3 Reaction direction down endpoint Syringe plate 1:1⊘1 dilution Following the 1⊘ minute preincubation of the tissue (enzyme) with the inhibitor, the samples are mixed with the substrate chromogen buffer by the ABA-1⊘⊘. Using the indicated instrument settings the ABA-1⊘⊘ automatically reads the color reaction and prints out the results in enzyme units after 15 minutes. 2. The enzyme activity can also be measured with Gilford 25⊘ spectrophotometer. This method is used for more accurate kinetic measurments. Instrument settings Lamp: visible Filter: no filter Wavelength: 412 nm Slit width: ⊘.2 mm Selection: small aperture Calibrated absorbance: 1.⊘ unit full scale Chart speed: ⊘.5 cm/min Reagents are added to the reference and sample side of a split curvette as follows. Reference Sample ⊘.8 ml ⊘.⊘5 M phosphate buffer ⊘.8 ml ⊘.⊘5M phosphate buffer ⊘.8 ml Chromogen-substrate buffer ⊘.8 ml Chromogen-substrate buffer 1⊘ microliter enzyme (tissue homogentate) The uninhibited activity of the enzyme (tissue homogenate) is first determined. Test drugs are made up in a suitable solvent and added in suitable dilutions to the buffer vehicle. The reaction rate is determined by the slope of the recorded absorbance change. The actual rate (moles/liter/min) can be calculated as described in the following formula rate (moles/liter/min) = slope/(1.36 x 1⊘⁴) In Vitro Inhibition of Butyrylcholinesterase Activity in Human Serum This assay can be used in conjunction with the acetylcholinesterase assay to determine the enzyme selectivity of various cholinesterase inhibitors. Butyrylcholinesterase (BChE), which is sometimes called pseudocholinesterase, preferentially hydrolyzes butyrylcholine. This enzyme is found in the highest amounts in serum, but its physiological role is not known. Ethopropazine and tetraisopropyl pyrophosphoramide (ISO-OMPA) are selective inhibitors of butyrylcholinesterase. An ex vivo experiment with ISO-OMPA has shown that inhibition of butyrylcholinesterase is not correlated with any significant acute cholinomimetic effects. Procedure A. Reagents 1. ⊘.⊘5 M Phosphate buffer, pH 7.2 a) 6.85 g NaH₂PO₄ . H₂O/1⊘⊘ ml distilled H₂O b) 13.4⊘ g Na₂HPO₄ . H₂O/1⊘⊘ ml distilled H₂O c) Add (a) to (b) until pH reaches 7.2 d) Dilute 1:1⊘ 2. Chromogen-substrate buffer a) 9.9 mg 5,5-dithiobisnitrobenzoic acid (DTND) b) 113 mg s-butyrylthiocholine chloride c) q.s. to 1⊘⊘ ml with ⊘.⊘5 M phosphate buffer, pH 7.2 (reagent 1). The resulting substrate concentration is 5mM and DTNB is ⊘.25 mM. 3. For most assays a 1.1 mM stock solution is made up in a suitable solvent and serially diluted, such that the final concentration in the preincubation step ranges from 1⊘⁻³ to 1⊘⁻⁶ M. Different concentrations may be used depending on the potency of the test drug. B. Enzyme Preparation A vial of lyophilized human Serum (Precilip, Biodynamics, Houston, Texas) is reconstituted in 3 ml of distilled water. A 1⊘ microliter aliquot of this suspension is added to 9⊘ microliter of the vehicle or various concentrations of the test drug and preincubated for 1⊘ minutes at room temperature. C. Assay Substantially the same procedure is used as described above in Section C of the Procedure used for determining the inhibition of acetylcholinesterase activity. Compound Inhibitory Concentration (1⊘⁻⁶M) Brain AChE Serum AChE Physostigmine (namely, (3aS-cis)-1,2,3,3a,8,8a-hexahydrol-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol, methyl carbamate) ⊘.1 ⊘.⊘6 [3aS-[3aα,5(R*),8aα]]-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol, (1-phenyl)ethyl carbamate 3.1 >1⊘⊘⊘ [3aS-[3aα,5(S*),8aα]]-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol, (1-phenyl)ethyl carbamate 1.2 ⊘.9 This utility is further demonstrated by the ability of these compounds to restore cholinergically deficient memory in the Dark Avoidance Assay, where they are generally active over a broader dose range than heretofore known compounds, a distinct therapeutic advantage. Dark Avoidance Assay In this assay mice are tested for their ability to remember an unpleasant stimulus for a period of 24 hours. A mouse is placed in a chamber that contains a dark compartment; a strong incandescent light drives it to the dark compartment, where an electric shock is administered through metal plates on the floor. The animal is removed from the testing apparatus and tested again, 24 hours later, for the ability to remember the electric shock. If scopolamine, an anticholinergic that is known to cause memory impairment, is administered before an animal's initial exposure to the test chamber, the animal re-enters the dark compartment shortly after being placed in the test chamber 24 hours later. This effect of scopolamine is countered by an active test compound, resulting in a greater interval before re-entry into the dark compartment. The results for active compound are expressed as the percent of a group of animals in which the effect of scopolamine is countered, as manifested by an increased interval between being placed in the test chamber and re-entering the dark compartment. The results of some of the compounds of this invention are presented in Table 2 along with the result for physostigmine. Compound Dose mg/kg Body Weight % of Animals With Scopolamine Induced Memory Deficit Reversed Physostigmine (namely, (3aS-cis)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol, methyl carbamate) ⊘.31 2⊘% [3aS-[3aα,5(R*),8aα]]-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol, (1-phenyl)ethyl carbamate ⊘.31 2⊘% [3aS-[3aα,5(S*),8aα]]-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol, (1-phenyl)ethyl carbamate 1.25 67% Additionally, some of the compounds of this invention exhibit antidepressant activities, which activities being particularly helpful for patients suffering from Alzheimer's disease. The antidepressant activities were evaluated in this invention on the basis of prevention of tetrabenazine-induced ptosis in mice, yohimbine toxicity potentiation and inhibition of ³H-norepinephrine uptake. The test methods and results are described below. Prevention Of Tetrabenazine-Induced Ptosis In Mice Tetrabenazine (TBZ) induces behavioral depression with concomitant ptosis in mice similar to reserpine. Antidepressant compounds, both monoamineoxidase inhibitors and tricyclics, are known to prevent or antagonize these effects and the degree of antagonism correlates with clinical efficacy. The prevention of TBZ-induced ptosis in mice is used as a preliminary screen for possible antidepressant activity. The method used in this invention is as follows: Male mice weighing 2⊘ to 3⊘ grams are used in test groups of five subjects. All compounds are dissolved or suspended with a suitable surfactant in distilled water and administered in volumes of 1⊘ ml/kg of body weight. TBZ solution is made from the methanesulfonate salt and the concentration is adjusted to enable administration of 6⊘ mg/kg of base by intraperitoneal (i.p.) injection. The pretreatment time is measured from the time of dosing to observation. Therefore, when a 3⊘-minute pretreat is utilized, drug and TBZ are given simultaneously. A control group receives solvent and TBZ at intervals identical to drug group. For a primary screen, the drug is administered i.p. and a group size of five is utilized. Eight animals/group are used for a dose range. Thirty minutes after TBZ, the subjects are placed in individual plastic containers (26.7 x 20.3 x 15.2 cm (1⊘.5 x 8 x 6 inches)) in the presence of white noise and one minute after the transfer, they are scored for ptosis on the following scale: Eyes closed = 4, eyes 3/4 closed = 3, eyes 1/2 closed = 2, eyes 1/4 closed = 1, eyes open = ⊘. The total score for each group of five in a primary screen will, therefore, be from ⊘ to 2⊘ and these scores are used as indications of drug activity. The vehicle control group score is used as a determinant of the validity of each test. If the control score is less than 17, the results are discarded and the test repeated. The calculation of percent inhibition of ptosis is: For ED 5⊘ estimation, four or five doses are administered in order to bracket the estimated value and only vehicle control scores of 27 to 32 are accepted to assure the accuracy of the ED 5⊘ estimation. Linear regression analysis is used to estimate ED 5⊘ values and 95% confidence intervals. The results of some of the compounds of this invention are shown in Table 3. Yohimbine Toxicity Potentiation The potentiation of yohimbine toxicity is considered an additional test for screening antidepressant drugs. The method used in this invention is as follows: Male mice weighing 2⊘ to 3⊘ grams are used. They are housed under standard laboratory conditions with free access to food and water. Compounds are dissolved in distilled water and a suitable surfactant is added in case of poor solubility. Yohimbine hydrochloride is dissolved in distilled water as well. Both compound and yohimbine are adminstered in a volume of 1⊘ mg/kg. Compounds and vehicle are administered orally 6⊘ minutes prior to a sublethal dose (3⊘ mg/kd s.c.) of yohimbine hydrochloride which alone causes death in about 1% of mice (4 out of 4⊘⊘). Ten mice per group are then placed in plastic cages (26 x 1⊘ x 16 cm) with food and water available ad libitum . Mortality rate is assessed 18 hours postdosing. ED 5⊘ is defined as dose of drug causing death in 5/1⊘ mice and is calculated by probit analysis. The results of some of the compounds of this invention are presented in Table 3. Compound % inhibition @ dose (mg/kg) TBZ YTP [3aS-[3aα,5(R*),8aα]]-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol, (1-phenyl)ethyl carbamate 35% @2⊘ 9⊘% @ 4⊘ [3aS-[3aα,5(S*),8aα]]-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol, (1-phenyl)ethyl carbamate 5⊘% @ 2⊘ --- ³H-Norepinephrine Uptake in Rat Whole Brain or Hypothalamic Synaptosomes This assay is used as a biochemical screen for potential antidepressants which block norepinephrine uptake. The neuronal re-uptake mechanism for norepinephrine (NE) is the most important physiological means for inactivating NE by removing the transmitter from the synaptic cleft. NE uptake is accomplished by a saturable, stereospecific, high-affinity ( K m =1⊘⁻⁷-1⊘⁻⁶M ), sodium-dependent, active transport system, which has been shown to exist in both peripheral and central nervous system tissues, using slice, homogenate and purified synaptosome preparations. NE uptake is potently inhibited by cocaine, phenethylamines and tricyclic antidepressants. It is also inhibited by ouabain, metabolic inhibitors and phenoxybenzamine. The inhibition of NE uptake by clinically effective tricyclic antidepressants is an important link in the catecholamine hypothesis of affective disorders. There are large regional variations in NE uptake which correlate with the endogenous levels of NE. The hypothalamus shows the highest level of NE and the greatest uptake. This region is used for further testing of compounds showing activity in whole brain preparations. Synaptosomal ³H-NE uptake is a useful marker for the integrity of noradrenergic neurons, after lesioning experiments, as well as an assay for compounds which potentiate the action of NE by blocking the reuptake mechanism. Procedure A. Animals: Male CR Wistar rats (1⊘⊘-125 g) B. Reagents 1. Krebs-Henseleit Bicarbonate Buffer, pH 7.4 (KHBB) Make a 1 liter batch, containing the following salts. grams/L mM NaCl 6.92 118.4 KCl ⊘.35 4.7 MgSO₄ . 7H₂O ⊘.29 1.2 KH₂PO₄ ⊘.16 2.2 NaHCO₃ 2.1⊘ 24.9 CaCl₂ ⊘.14 1.3 Prior to use add: Dextrose 2 mg/ml 11.1 Iproniazid phosphate ⊘.3⊘ mg/ml ⊘.1 Aerate for 6⊘ min. with 95% O₂/5% CO₂,check pH (7.4 ± ⊘.1). 2. ⊘.32 M Sucrose: 21.9 g of sucrose, q.s. to 2⊘⊘ ml. 3. L(-)-Norepinephrine bitartrate is procured form a commercial source. A ⊘.1mM stock solution is made up in ⊘.⊘1 N HCl. This is used to dilute the specific activity of the radiolabeled NE. 4. Levo-[Ring-2,5,6-³H]-Norepinephrine (4⊘-5⊘ Ci/mmol) is obtained from a commercial course. The final desired concentration of ³H-NE in the assay is 5⊘nM. The dilution factor is ⊘.8; therefore the KHBB is made up to contain 62.5 nM [³H]-NE. Add to 1⊘⊘ ml of KHBB: A. 59.4 microliter of ⊘.1 mM NE = 59.4 nM B. ⊘.31 nmole of ³H-NE = 3.1 nM 62.5 nM 5. For most asays, a 1 mM stock solution of the test compound is made up in a suitable solvent and serially diluted such that the final concentration in the assay ranges from 2 x1⊘⁻⁸ to 2 x1⊘⁻⁵M. Seven concentrations are used for each assay. Higher or lower concentrations may be used depending on the potency of the test compound. C. Tissue Preparation Male Wister rats are decapitated and brains rapidly removed. Either whole brain minus cerebella or hypothalamus is weighed and homogenized in 9 volumes of ice-cold ⊘.32 M sucrose using a Potter-Elvejhem homogenizer. Homogenization should be done with 4-5 up and down strokes at medium speeds to minimize synaptosome lysis. The homogenate is centrifuged at 1⊘⊘⊘ g for 1⊘ min at ⊘-4°C. The supernatant (S₁) is decanted and is used for uptake experiments. D. Assay 8⊘⊘ microliter KHBB containing [³H]-NE 2⊘ microliter Vehicle or appropriate drug concentration 2⊘⊘ microliter Tissue suspension Tubes are incubated at 37°C under a 95% O₂/5% CO₂ atmosphere for 5 minutes. For each assay, 3 tubes are incubated with 2⊘ microliter of vehicle at ⊘°C in an ice bath. After incubation all tubes are immediately centrifuged at 4⊘⊘⊘ g for 1⊘ minutes. The supernatant fluid is aspirated and the pellets dissolved by adding 1 ml of a solubilizer. The tubes are vigorously vortexed, decanted into scintillation vials, and counted in 1⊘ ml of Liquiscint scintillation counting cocktail. Active uptake is the difference between cpm at 37°C and ⊘°C. The percent inhibition at each drug concentration is the mean of three determinations. IC 5⊘ values are devied from log-probit analysis. The results of some of the compounds of this invention are presented in Table 4 along with the result for physostigmine. Compound Reuptake Inhibition (1⊘⁻⁶M) of neurotransmitters Norepinephrine Physostigmine (namely, (3aS-cis)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol, methyl carbamate) > 2⊘ [3aS-[3aα,5(R*),8aα]]-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol, (1-phenyl)ethyl carbamate 2.2 [3aS-[3aα,5(S*),8aα]]-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol, (1-phenyl)ethyl carbamate 12 Furthermore, the compounds of this invention are in general less toxic than heretofore known compounds such as tacrine and physostigmine, making them therapeutically more acceptable. LD 5⊘ is determined by the dose (mg/kg) at which 5⊘% of the test animals die within 24 hours. In many cases this dose is an approximation. The results of some of the compounds of this invention are presented in Table 5 along with the result for physostigmine. Compound LD 5⊘ (mg/kg, i.p.) Physostigmine (namely, (3aS-cis)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol, methyl carbamate) ∼ 3 [3aS-[3aα,5(R*),8aα]]-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol, (1-phenyl)ethyl carbamate > 4⊘ < 8⊘ [3aS-[3aα,5(S*),8aα]]-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol, (1-phenyl)ethyl carbamate ∼ 4⊘ Compounds I of the present invention are also useful as analgesic agents due to their ability to alleviate pain in mammals. The activity of the compounds is demonstrated in the 2-phenyl-1,4-benzoquinone-induced writhing (PQW) test in mice, a standard assay for analgesia [Proc. Soc. Exptl. Biol. Med., 95, 729 (1957)] and in modified Haffner's analgesia. The latter assay is used to evaluate analgesic activity by measuring drug-induced changes in the sensitivity of mice to pressure stress by placing an artery clip (6.35 cm = 2 1/2 inches long) on their tail. The procedure used is a modification of the test developed by Haffner, Dtsch. Med. Wschr. 55 , 731 (1929), and it is described below. METHOD : Male mice (Charles River, CD-1) from 18-3⊘ grams are used for the test. An artery clip is applied to the root of the tail of a mouse (approximately 1.27 cm 1/2 inch from the body) to induce pain. The animal quickly responds to this noxious stimuli by biting the clip or the location of the clip. This reaction time, the interval between stimulus onset and response, is recorded in 1/1⊘-second increments by a stop watch. For a time response, the screening dose (25 mg/kg) is administered subcutaneously (1⊘ ml/kg) to the animal receiving food and water ad libitum before testing. Animals receiving the compound orally are fasted 18-24 hours before drug administration. Drug to be tested is prepared with distilled water and if insoluble, one drop of a surfactant is added. Twenty-eight animals (seven/group) are administered the drug 15, 3⊘, 45 and 6⊘ minutes prior to testing. The cut-off time (CO) is determined by taking the (x) average + (3) standard (SD) deviation of the combined response latencies of the control mice in all time periods. Listed in Table 6 are test results of the analgesic activities of a compound of this invention along with those of eseroline salicylate used as a reference compound. As compared with eseroline, the compounds of this invention are much less toxic, have a longer lasting analgesic effect, have less physical dependence liability and are more stable. CO = x + 3 SD (seconds) Any reaction time, in subsequent drug tests, which is greater than the CO (for the same time period) therefore exceeds 99% of a normal Gaussian distribution and is called "positive reponse" indicative of analgesic activity. A time response indicates the period of greatest analgesic effect after dosing. The ED 5⊘ is determined at the peak time of drug activity. A minimum of three dose groups are used. ED 5⊘ 's are calculated using computer analysis. ANALGESIC ACTIVITY (ED 5⊘ ) Compound PQW Modified Haffner's Analgesia 7-bromo-(3aS-cis)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol ⊘.⊘41 mg/kg,sc ⊘<-> ⊘.55 mg/kg,sc .36 mg/kg,po 7-bromo-(3aS-cis)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol trimethylacetate hydrochloride ⊘.8 mg/kg,sc ⊘.6 mg/kg,sc eseroline salicylate (reference compound) ⊘.52 mg/kg,sc ⊘.18 mg/kg,sc Effective quantities of the compounds of the invention may be administered to a patient by any of the various methods, for example, orally as in capsules or tablets, parenterally in the form of sterile solutions or suspensions, and in some cases intravenously in the form of sterile solutions. The free base final products, while effective themselves, may be formulated and administered in the form of their pharmaceutically acceptable acid addition salts for purposes of stability, convenience of crystallization or increased solubility. Acids useful for preparing the pharmaceutically acceptable acid addition salts of the invention include inorganic acids such as hydrochloric, hydrobromic, sulfuric, nitric, phosphoric and perchloric acids, as well as organic acids such as tartaric, citric, acetic, succinic, salicylic, maleic, fumaric and oxalic acids. The active compounds of the present invention may be orally administered, for example, with an inert diluent or with an edible carrier, or they may be enclosed in gelatin capsules, or they may be compressed into tablets. For the purpose of oral therapeutic administration, the active compounds of the invention may be incorporated with excipients and used in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers or chewing gum. These preparations should contain at least ⊘.5% of active compounds, but may be varied depending upon the particular form and may conveniently be between 4% to about 7⊘% of the weight of the unit. The amount of active compound in such composition is such that a suitable dosage will be obtained. Preferred compositions and preparations according to the present invention are prepared so that an oral dosage unit form contains between 1.⊘-3⊘⊘ milligrams of active compound. The tablets, pills, capsules or troches may also contain the following ingredients: a binder such as micro-crystalline cellulose, gum tragacanth or gelatin; and excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel or cornstarch; a lubricant such as magnesium stearate or Sterotex; a glidant such as colloidal silicon dioxide; and a sweetening agent such as sucrose or saccharin may be added or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil. Other dosage unit forms may contain other various materials which modify the physical form of the dosage unit, for example, as coatings. Thus tablets or pills may be coated with sugar, shellac, or other enteric coating agents. A syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes, coloring and flavors. Materials used in preparing these various compositions should be pharmaceutically pure and non-toxic in the amounts used. For the purposes of parenteral therapeutic administration, the active compounds of the invention may be incorporated into a solution or suspension. These preparations should contain at least ⊘.1% of active compounds, but may be varied depending upon the particular form and may conveniently be between 4% and about 7⊘% of the weight of the unit. The amount of active compound in such compositions is such that a suitable dosage will be obtained. Preferred compositions and preparations according to the present invention are prepared so that a parenteral dosage unit contains between ⊘.5 to 1⊘⊘ milligrams of active compounds. The solutions or suspensions may also include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The parenteral preparation can be enclosed in disposable syringes or multiple dose vials made of glass or plastic. Examples of the compounds of the invention include those listed below as well as the 3aR-cis isomers thereof and mixtures of the 3aS-cis and 3aR-cis isomers including the racemic mixtures: 7-chloro-(3aS-cis)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-pyrrolo[2,3-b]indol-5-ol, methyl carbamate ester; 7-bromo-(3aS-cis)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-pyrrolo[2,3-b]indol-5-ol, methyl carbamate ester; (3aS-cis)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-pyrrolo[2,3-b]indol-5-ol, benzyl carbamate ester; (3aS-cis)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-pyrrolo[2,3-b]indol-5-ol, (2-phenyl)ethyl carbamate ester; [3aS-[3aα,5(R*),8aα]]-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol, (1-phenyl)ethyl carbamate ester; [3aS-[3aα,5(S*),8aα]]-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol, (1-phenyl)ethyl carbamate ester; 7-chloro-[3aα,5(R*),8aα]-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-pyrrolo[2,3-b]indol-5-ol, (1-phenyl)ethyl carbamate ester; 7-bromo-[3aα,5(R*),8aα]-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-pyrrolo[2,3-b]indol-5-ol, (1-phenyl)ethyl carbamate; 7-chloro-(3aS-cis)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-pyrrolo[2,3-b]indol-5-ol, cyclohexyl carbamate ester; 7-bromo-(3aS-cis)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-pyrrolo[2,3-b]indol-5-ol, cyclohexyl carbamate ester; 6-bromo-(3aS-cis)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-pyrrolo[2,3-b]indol-5-ol, 3-chlorophenyl carbamate ester; 7-bromo-(3aS-cis)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-pyrrolo[2,3-b]indol-5-ol acetate; 7-bromo-(3aS-cis)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-pyrrolo[2,3-b]indol-5-ol heptanoate; The present invention will be described below in further detail with reference to the following examples. EXAMPLE 1 7-Chloro-(3aS-cis)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-pyrrolo[2,3-b]indol-5-ol, methyl carbamate ester A degassed solution of eserine (5.⊘ g) in 6⊘ ml of methanol and 2 drops of concentrated hydrochloric acid was treated with N-chlorosuccinimide (2.6 g) in one portion with stirring. After 4 hours the solution was evaporated and the residue was purified by flash chromatography (silica gel, 4:1 ethyl acetate/methanol) to an oil. This oil was crystallized from hot ether to give 4.1 g of crystals, mp 129-13⊘°C. ANALYSIS: Calculated for C₁₅H₂ ⊘ ClN₃O₂: 58.15%C 6.5⊘%H 13.56%N Found: 58.18%C 6.54%H 13.59%N EXAMPLE 2 7-Bromo-(3aS-cis)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-pyrrolo[2,3-b]indol-5-ol, methyl carbamate ester A degassed solution of eserine (2.⊘ g) in 5⊘ ml of methanol and 2 drops of 48% HBr was treated with N-bromosuccinimide (1.4 g) in one portion. After 1 hour at room temperature, the solution was evaporated and the residue was purified by flash chromatography (silica gel, 4:1 ethyl acetate/methanol) to give an oil. This oil was crystallized from hot ether to give 1.6 g of crystals, mp 121-122°C. ANALYSIS: Calculated for C₁₅H₂ ⊘ BrN₃O₂: 5⊘.85%C 5.69%H 11.86%N Found: 5⊘.73%C 5.68%H 11.76%N EXAMPLE 3 (3aS-cis)-1,2,3,3a,8,8a-Hexahydro-1,3a,8-trimethyl-pyrrolo[2,3-b]indol-5-ol, benzyl carbamate ester A solution of eseroline (1.7 g) and benzyl isocyanate (1.2 g) in 7⊘ ml of degassed tetrahydrofuran was treated with a catalytic chip of sodium metal and stirred at room temperature for 1⊘ hours. The volatiles were removed and the residue was recrystallized from acetone/petroleum ether to give 2.1 of a powder, mp 167-169°C. ANALYSIS: Calculated for C₂₁H₂₅N₃O₂: 71.76%C 7.17%H 11.95%N Found: 71.55%C 6.97%H 11.95%N EXAMPLE 4 (3aS-cis)-1,2,3,3a,8,8a-Hexahydro-1,3a,8-trimethyl-pyrrolo[2,3-b]indol-5-ol, (2-phenyl)ethyl carbamate ester A solution of eseroline (1.3 g) and phenylethyl isocyanate (1.⊘3 g) in 5⊘ ml of degassed tetrahydrofuran was treated with a catalytic chip of sodium metal. The solution was heated to relux for 4 hours and thereafter evaporated. The residue was recrystallized from acetone/petroleum ether to give 1.7 g of needles, mp 152-155°C. ANALYSIS: Calculated for C₂₂H₂₇N₃O₂: 72.29%C 7.45%H 11.49%N Found: 72.33%C 7.49%H 11.56%N EXAMPLE 5 [3aS-[3aα,5(R*),8aα]]-1,2,3,3a,8,8a-Hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol, (1-phenyl)ethyl carbamate ester A degassed solution containing eseroline (1.7 g) and S-(-)-α-methylbenzyl isocyanate (1.⊘ g) in 5⊘ ml of dry tetrahydrofuran was treated with a catalytic chip of sodium metal and stirred at room temperature for 1 hour. This solution was heated under reflux for 5 hours and evaporated to a foam. This foam was purified by flash chromatography (alumina, ethyl acetate) and thereafter recrystallized from ether/petroleum ether to give 1.6 g of a powder, mp 113-114°C. ANALYSIS: Calculated for C₂₂H₂₇N₃O₂: 72.29%C 7.45%H 11.49%N Found: 72.37%C 7.68%H 11.37%N EXAMPLE 6 [3aS-[3aα,5(S*),8aα]]-1,2,3,3a,8,8a-Hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol, (1-phenyl)ethyl carbamate ester A degassed solution containing eseroline (1.5 g) and R-(+)-α-methylbenzyl isocyanate (1.⊘ g) in 6⊘ ml of dry tetrahydrofuran was treated with a catalytic chip of sodium metal and stirred at room temperature for 1 hour. This solution was heated to reflux for 5 hours and thereafter evaporated. The residue was purified by flash chromatography (alumina, ethyl acetate) to a powder. This powder was recrystallized from ether/petroleum ether to give 2.⊘ g of crystals, mp 151-153°C. ANALYSIS: Calculated for C₂₂H₂₇N₃O₂: 72.29%C 7.45%H 11.49%N Found: 72.1⊘%C 7.63%H 11.36%N EXAMPLE 7 7-Chloro-[3aα,5(R*),8aα]-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-pyrrolo[2,3-b]indol-5-ol, (1-phenyl)ethyl carbamate ester A degassed solution containing 7-chloroeseroline (1.3 g) and S(-)-α-methylbenzyl isocyanate (1.⊘ g) in 6⊘ ml of dry tetrahydrofuran was treated with a catalytic chip of sodium metal and stirred at 5⊘° for 3 hours. This solution was evaporated and the residue recrystallized twice from dichloromethane to give 1.4 g of crystals, mp 172-173°C. ANALYSIS: Calculated for C₂₂H₂₆ClN₃O₂: 66.⊘7%C 6.55%H 1⊘.5⊘%N Found: 65.81%C 6.59%H 1⊘.43%N EXAMPLE 8 7-Bromo-[3aα,5(R*),8aα]-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol, (1-phenyl)ethyl carbamate ester A degassed solution of 7-bromoeseroline (1.5 g) and (S)-(-)-α-methylbenzyl isocyanate (1.⊘ g) in 6⊘ ml of dry tetrahydrofuran was treated with a catalytic chip of sodium metal and stirred at 6⊘° for 4 hours. The resulting solution was evaporated and the remaining powder recrystallized twice from chloroform to give 1.4 g of crystals, mp 183-185°. ANALYSIS: Calculated for C₂₂H₂₆BrN₃O₂: 59.46%C 5.89%H 9.45%N Found: 59.1⊘%C 5.8⊘%H 9.33%N EXAMPLE 9 7-Chloro-(3aS-cis)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol, cyclohexyl carbamate ester A degassed solution containing 7-chloroeseroline (1.5 g) and cyclohexyl isocyanate (1.5 g) in 5⊘ ml of dry tetrahydrofuran was treated with a catalytic chip of sodium metal and stirred at room temperature overnight. This solution was evaporated and the residue purified by column chromatography (neutral alumina, 9:1 ethyl acetate/dichloromethane) to give an oil. This oil was crystallized from ether to give 1.2 g of crystals, mp 154-156°. ANALYSIS: Calculated for C₂ ⊘ H₂₈ClN₃O₂: 63.56%C 7.46%H 11.12%N Found: 63.38%C 7.6⊘%H 1⊘.83%N EXAMPLE 10 7-Bromo-(3aS-cis)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-pyrrolo[2,3-b]indol-5-ol, cyclohexyl carbamate ester A degassed solution containing 7-bromoeseroline (1.5 g) and cyclohexyl isocyanate (1.5 g) in 6⊘ ml of dry tetrahydrofuran was treated with a catalytic chip of sodium metal and stirred at 5⊘° for 3 hours. This solution was evaporated and the residue purified by column chromatography (alumina, 5:1 ethyl acetate/dichloromethane) to give 2.1 g of powder. This powder was crystallized from ether/petroleum ether to give 1.9 g of crystals, mp 163-164°. ANALYSIS: Calculated for C₂ ⊘ H₂₈BrN₃O₂: 56.68%C 6.68%H 9.95%N Found: 56.98%C 6.6⊘%H 9.88%N EXAMPLE 11 7-Chloro-(3aS-cis)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-pyrrolo[2,3-b]indol-5-ol (7-Chloroeseroline) A mixture prepared from 2.4 g of 7-chloro-(3as-cis)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2 , 3-b]indol-5-ol, methyl carbamate ester in 5 ml of ethanol and 1.⊘ g of sodium hydroxide in 1⊘ ml of water was degassed and stirred at 4⊘° for 4 hours. The resulting solution was quenched with 1⊘⊘ ml of saturated sodium bicarbonate solution and thereafter extracted with ethyl acetate (2 x 1⊘⊘ ml). The combined extracts were dried over anhydrous magnesium sulfate, filtered and evaporated to give 1.7 g of powder. An analytical sample was prepared by sublimation [0,13 mbar (0.1 mmHg), 145°C] of the powder to give crystals, mp 152-154°. ANALYSIS: Calculated for C₁₃N₁₇ClN₂O: 61.77%C 6.78%H 11.⊘8%N Found: 61.73%C 6.74%H 11.⊘2%N EXAMPLE 12 7-Bromo-(3aS-cis)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol (7-Bromoeseroline) A mixture prepared from 5.1 g of 7-bromo-(3aS-cis)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol, methyl carbamate ester in 5 ml of ethanol and 2.⊘ g of sodium hydroxide in 2⊘ ml of water was degassed and stirred at room temperature for 6 hours. The resulting solution was quenched with 2⊘⊘ ml of saturated sodium bicarbonate solution and thereafter extracted with ethyl acetate (3 x 1⊘⊘ ml). The combined extracts were dried over anhydrous magnesium sulfate, filtered and evaporated to give 4.1 g of powder. An analytical sample was prepared by sublimation [0,13 mbar (0.1 mmHg), 160°C] of the powder to give crystals, mp 175-177°C. ANALYSIS: Calculated for C₁₃H₁₇BrN₂O: 52.53%C 5.76%H 9.42%N Found: 52.46%C 5.63%H 9.44%N EXAMPLE 13 7-Bromo-(3aS-cis)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol, 3-chlorophenyl carbamate ester fumarate A degassed mixture of 2.5⊘ g of 7-bromo-(3aS-cis)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol, 1.53 g of 3-chlorophenylisocyanate and ⊘.2 ml of triethylamine in 15⊘ ml of dry benzene was stirred under nitrogen for 5 hours. The solvent was then evaporated in vacuo and the residue was dissolved in 5⊘ ml of ether. To this was added a solution of 1.⊘ g of fumaric acid in methanol followed by petroleum ether to precipitate the product as the fumarate salt. This was recrystallized from a solvent mixture of methanol/ether/petroleum ether to afford 3.⊘ g of crystals, mp 17⊘°C, dec. ANALYSIS: Calculated for C₂ ⊘ H₂₁BrClN₃O₂·C₄H₄O₄: 5⊘.85%C 4.45%H 7.41%N Found: 5⊘.68%C 4.75%H 7.48%N EXAMPLE 14 7-Bromo-(3aS-cis)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol trimethylacetate hydrochloride A solution of ⊘.69 g of trimethylacetic acid and 1.1⊘ g of 1,1'-carbonyldiimidazole in 1⊘⊘ ml of dry, degassed tetrahydrofuran was refluxed for 1 hour. The reaction mixture was cooled to room temperature, and 2.⊘⊘ g of 7-bromo-(3aS)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol was added. The reaction mixture was stirred overnight and then the solvent was removed in vacuo. The residue was triturated with dichloromethane/petroleum ether to precipitate the imidazole by-product. This was filtered, and the filtrate containing the desired product was concentrated to an oil. The oil was purified by chromatography over neutral alumina using dichloromethane as eluent. The fractions containing the purified product were combined and the solvent was removed to provide 2.1 g of viscous oil. This was dissolved in ether, and the solution was cooled in a dry ice/acetone bath and made acidic by addition of ethereal hydrogen chloride. Addition of petroleum ether caused the product to precipitate. Recrystallization twice from ether/ethanol furnished pure crystals of 7-bromo-(3aS-cis)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol trimethylacetate hydrochloride, mp 214-215°C. ANALYSIS: Calculated for C₁₈H₂₆BrN₂O₂·HCl: 51.63%C 6.5⊘%H 6.69%N Found: 51.6⊘%C 6.26%H 6.71%N EXAMPLE 15 7-Bromo-(3aS-cis)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol acetate hydrochloride A mixture of 3.⊘ g of 7-bromo-eseroline and 86 mg of sodium bicarbonate in 3⊘ ml of tetrahydrofuran was degassed and kept under N₂ at ⊘°C. Potassium t-butoxide (12⊘ mg) was charged in one portion and the mixture was stirred for 2⊘ minutes. Then 1.⊘8 g of acetic anhydride was added dropwise. After 3⊘ minutes of stirring, thin layer chromatography indicated the reaction was complete. The mixture was quenched with methanol (2 ml) and thereafter concentrated to a solid. This product was extracted into ether (5⊘ ml) and the insolubles were filtered. Treatment with a solution of HCl (generated by acetyl chloride, 8⊘⊘ mg; MeOH, 4 ml; ether, 75 ml) with stirring at ⊘°C resulted in crystallization of the hydrochloride salt (2.⊘ g), mp 218-221° dec. ANALYSIS: Calculated for C₁₅H₁₉BrN₂O₂·HCl: 47.95%C 5.37%H 7.46%N Found: 47.66%C 5.35%H 7.57%N

Claims: Claims for the following Contracting States : BE, CH, DE, FR, GB, GR, IT, LI, LU, NL, SE A compound of the formula I where Z is H and R is where R₂ is phenyl-C₁-C₆-alkyl, wherein the phenyl may be substituted with 1, 2 or 3 substituent groups each of which being independently C₁-C₆-alkyl, halogen, nitro, C₁-C₆-alkoxy, hydroxy or trifluoromethyl, or where Z is halogen or C₁-C₆-alkyl, R is H or where R₄ is C₁-C₆-alkyl, or phenyl, or R is wherein R₃ is C₁-C₆-alkyl, C₃-C₆-cycloalkyl, phenyl or phenyl-C₁-C₆-alkyl, wherein the phenyl may be substituted as indicated above, or the 3aR-cis isomer thereof or a mixture of the two isomers including the racemic mixture or a pharmaceutically acceptable acid addition salt thereof. A compound as defined in Claim 1, where Z is hydrogen or halogen and R is R₂HNCO- or R₃HNCO-, where R₂ and R₃ are as defined. A compound as defined in Claim 1 which is [3aS-[3aα,5(R*),8aα]]-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo-[2,3-b]indol-5-ol, (1-phenyl)ethyl carbamate. A compound as defined in Claim 1, which is [3aS-[3aα,5(S*),8aα]]-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol, (1-phenyl)ethyl carbamate. A pharmaceutical composition comprising an effective amount of a compound as defined in Claim 1 and a suitable carrier therefore. Use of a compound as defined in Claim 1 for the preparation of a medicament having memory enhancing or pain alleviating activity. A process for the preparation of a compound of the formula I as defined in Claim 1, which comprises a) reacting a compound of the formula (XI) where Z is hydrogen, with an isocyanate of the formula R₂-N = C = O, wherein R₂ is phenyl-C₁-C₆-alkyl, wherein the phenyl may be substituted as indicated in Claim 1, to afford a compound of the formula (I), wherein R is the group R₂HNCO, and Z and R₂ are as defined above, b) reacting a compound of the formula (XI), where Z is halogen or C₁-C₆-alkyl, with an isocyanate of the formula R₃-N = C = O, wherein R₃ is C₁-C₆-alkyl, C₃-C₆-cycloalkyl, phenyl or phenyl-C₁-C₆-alkyl, wherein the phenyl may be substituted as indicated in Claim 1, to afford a compound of the formula (I), wherein R is the group R₃HNCO-, and Z and R₃ are as defined above, or c) reacting a compound of the formula (XI) wherein Z is halogen or C₁-C₆-alkyl with a mixture of a carboxylic acid of the formula R₄COOH, wherein R₄ is C₁-C₆-alkyl or phenyl, and 1,1'-carbonyldiimidazole, to afford a compound of the formula (I), wherein R is the group R₄CO-, and Z and R₄ are as defined above. Claims for the following Contracting States : AT, ES A process for the preparation of a compound of the formula (I) where Z is H and R is where R₂ is phenyl-C₁-C₆-alkyl, wherein the phenyl may be substituted with 1, 2 or 3 substituent groups each of which being independently C₁-C₆-alkyl, halogen, nitro, C₁-C₆-alkoxy, hydroxy or trifluoromethyl, or where Z is halogen or C₁-C₆-alkyl, R is H or where R₄ is C₁-C₆-alkyl, or phenyl, or R is wherein R₃ is C₁-C₆-alkyl, C₃-C₆-cycloalkyl, phenyl or phenyl-C₁-C₆-alkyl, wherein the phenyl may be substituted as indicated above, or the 3aR-cis isomer thereof or a mixture of the two isomers including the racemic mixture or a pharmaceutically acceptable acid addition salt thereof, which comprises a) reacting a compound of the formula (XI) where Z is hydrogen, with an isocyanate of the formula R₂-N = C = O, wherein R₂ is phenyl-C₁-C₆-alkyl, wherein the phenyl may be substituted as indicated in Claim 1, to afford a compound of the formula (I), wherein R is the group R₂HNCO, and Z and R₂ are as defined above, b) reacting a compound of the formula (XI), where Z is halogen or C₁-C₆-alkyl, with an isocyanate of the formula R₃-N = C = O, wherein R₃ is C₁-C₆-alkyl, C₃-C₆-cycloalkyl, phenyl or phenyl-C₁-C₆-alkyl, wherein the phenyl may be substituted as indicated in Claim 1, to afford a compound of the formula (I), wherein R is the group R₃HNCO-, and Z and R₃ are as defined above, or c) reacting a compound of the formula (XI) wherein Z is halogen or C₁-C₆-alkyl with a mixture of a carboxylic acid of the formula R₄COOH, wherein R₄ is C₁-C₆-alkyl or phenyl, and 1,1'-carbonyldiimidazole, to afford a compound of the formula (I), wherein R is the group R₄CO-, and Z and R₄ are as defined above. A process as defined in Claim 1, where Z is hydrogen or halogen and R is R₂HNCO- or R₃HNCO-, where R₂ and R₃ are as defined. A process as defined in Claim 1, wherein the compound [3aS-[3aα,5(R*),8aα]]-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol, (1-phenyl)ethyl carbamate is prepared. A process as defined in Claim 1, wherein the compound [3aS-[3aα,5(S*),8aα]]-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol, (1-phenyl)ethyl carbamate is prepared. Use of a compound of the formula (I) as defined in Claim 1 for the preparation of a medicament having memory enhancing and/or pain alleviating activity.

Inventors: CHIANG YULIN, GLAMKOWSKI EDWARD J, HAMER RUSSEL RICHARD LEE, HELSLEY GROVER CLEVELAND, CHIANG, YULIN, GLAMKOWSKI, EDWARD J., HAMER, RUSSEL RICHARD LEE, HELSLEY, GROVER CLEVELAND
Applicants: HOECHST ROUSSEL PHARMA, HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED
Application year: 1987
Main classification: C07D487
IPC codes: C07D487, A61P25, A61K31